Peringatan Keamanan

Side effects include hyperkalemia, cough, hypotension, increased SrCr, and dizziness. Dizziness, diarrhea, vision disturbance, hypotension and angioedema

Omapatrilat

DB00886

small molecule investigational

Deskripsi

Omapatrilat is an investigational drug that inhibits both neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE). The inhibition of NEP elevates natriuretic peptide levels, increasing excretion of sodium in urine, dilating blood vessels, and reducing preload and ventricular remodeling. This drug from BMS was not approved by the FDA due to angioedema safety concerns.

Struktur Molekul 2D

Berat 408.53
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

The absolute oral bioavailability of omapatrilat is 20% to 30% and the absorption is not affected by food intake.

Metabolisme

Hepatic

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

836 Data
Alfuzosin Alfuzosin may increase the hypotensive activities of Omapatrilat.
Amifostine Omapatrilat may increase the hypotensive activities of Amifostine.
Diazoxide Diazoxide may increase the hypotensive activities of Omapatrilat.
Methylphenidate Methylphenidate may decrease the antihypertensive activities of Omapatrilat.
Dexmethylphenidate Dexmethylphenidate may decrease the antihypertensive activities of Omapatrilat.
Obinutuzumab Omapatrilat may increase the hypotensive activities of Obinutuzumab.
Pentoxifylline Pentoxifylline may increase the hypotensive activities of Omapatrilat.
Rituximab Omapatrilat may increase the hypotensive activities of Rituximab.
Angiotensin 1-7 Omapatrilat may decrease the antihypertensive activities of Angiotensin 1-7.
Yohimbine Yohimbine may decrease the antihypertensive activities of Omapatrilat.
Epicaptopril Epicaptopril may decrease the antihypertensive activities of Omapatrilat.
Siponimod Siponimod may decrease the antihypertensive activities of Omapatrilat.
Reserpine Omapatrilat may decrease the antihypertensive activities of Reserpine.
Torasemide Omapatrilat may decrease the antihypertensive activities of Torasemide.
Nitroprusside Omapatrilat may decrease the antihypertensive activities of Nitroprusside.
Minoxidil Omapatrilat may decrease the antihypertensive activities of Minoxidil.
Clozapine Clozapine may decrease the antihypertensive activities of Omapatrilat.
Imipramine Imipramine may decrease the antihypertensive activities of Omapatrilat.
Chlorpromazine Chlorpromazine may decrease the antihypertensive activities of Omapatrilat.
Doxazosin Omapatrilat may decrease the antihypertensive activities of Doxazosin.
Dexmedetomidine Dexmedetomidine may decrease the antihypertensive activities of Omapatrilat.
Mecamylamine Omapatrilat may decrease the antihypertensive activities of Mecamylamine.
Thioridazine Thioridazine may decrease the antihypertensive activities of Omapatrilat.
Phentolamine Phentolamine may decrease the antihypertensive activities of Omapatrilat.
Sufentanil Sufentanil may decrease the antihypertensive activities of Omapatrilat.
Nitroglycerin Omapatrilat may decrease the antihypertensive activities of Nitroglycerin.
Isoflurane Isoflurane may decrease the antihypertensive activities of Omapatrilat.
Tolazoline Tolazoline may decrease the antihypertensive activities of Omapatrilat.
Fenoldopam Omapatrilat may decrease the antihypertensive activities of Fenoldopam.
Propofol Propofol may decrease the antihypertensive activities of Omapatrilat.
Remifentanil Remifentanil may decrease the antihypertensive activities of Omapatrilat.
Phenoxybenzamine Omapatrilat may decrease the antihypertensive activities of Phenoxybenzamine.
Methyldopa Omapatrilat may decrease the antihypertensive activities of Methyldopa.
Guanfacine Omapatrilat may decrease the antihypertensive activities of Guanfacine.
Bretylium Omapatrilat may decrease the antihypertensive activities of Bretylium.
Halothane Halothane may decrease the antihypertensive activities of Omapatrilat.
Terazosin Omapatrilat may decrease the antihypertensive activities of Terazosin.
Desflurane Desflurane may decrease the antihypertensive activities of Omapatrilat.
Bromocriptine Bromocriptine may decrease the antihypertensive activities of Omapatrilat.
Sevoflurane Sevoflurane may decrease the antihypertensive activities of Omapatrilat.
Clomipramine Clomipramine may decrease the antihypertensive activities of Omapatrilat.
Hydralazine Omapatrilat may decrease the antihypertensive activities of Hydralazine.
Lofexidine Omapatrilat may decrease the antihypertensive activities of Lofexidine.
Rotigotine Rotigotine may decrease the antihypertensive activities of Omapatrilat.
Riociguat Omapatrilat may decrease the antihypertensive activities of Riociguat.
Isoxsuprine Isoxsuprine may decrease the antihypertensive activities of Omapatrilat.
Indoramin Omapatrilat may decrease the antihypertensive activities of Indoramin.
Moxonidine Omapatrilat may decrease the antihypertensive activities of Moxonidine.
Selpercatinib Selpercatinib may decrease the antihypertensive activities of Omapatrilat.
Naxitamab Naxitamab may decrease the antihypertensive activities of Omapatrilat.
Levamlodipine Omapatrilat may decrease the antihypertensive activities of Levamlodipine.
Amphetamine Amphetamine may decrease the antihypertensive activities of Omapatrilat.
Aliskiren The risk or severity of hypotension, hyperkalemia, and nephrotoxicity can be increased when Aliskiren is combined with Omapatrilat.
Allopurinol The risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Omapatrilat.
Aprotinin Aprotinin may decrease the antihypertensive activities of Omapatrilat.
Azathioprine The risk or severity of myelosuppression, anemia, and severe leukopenia can be increased when Omapatrilat is combined with Azathioprine.
Ertugliflozin The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Ertugliflozin is combined with Omapatrilat.
Canagliflozin The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Omapatrilat.
Dapagliflozin The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Dapagliflozin is combined with Omapatrilat.
Empagliflozin The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Omapatrilat.
Dapoxetine Dapoxetine may increase the orthostatic hypotensive activities of Omapatrilat.
Drospirenone Omapatrilat may increase the hyperkalemic activities of Drospirenone.
Eplerenone Eplerenone may increase the hyperkalemic activities of Omapatrilat.
Everolimus The risk or severity of adverse effects can be increased when Everolimus is combined with Omapatrilat.
Sirolimus The risk or severity of adverse effects can be increased when Sirolimus is combined with Omapatrilat.
Semuloparin The risk or severity of hyperkalemia can be increased when Omapatrilat is combined with Semuloparin.
Icatibant Icatibant may decrease the antihypertensive activities of Omapatrilat.
Lithium citrate The serum concentration of Lithium citrate can be increased when it is combined with Omapatrilat.
Lithium carbonate The serum concentration of Lithium carbonate can be increased when it is combined with Omapatrilat.
Lithium hydroxide The serum concentration of Lithium hydroxide can be increased when it is combined with Omapatrilat.
Tizanidine The risk or severity of hypotension can be increased when Tizanidine is combined with Omapatrilat.
Tolvaptan Tolvaptan may increase the hyperkalemic activities of Omapatrilat.
Trimethoprim Trimethoprim may increase the hyperkalemic activities of Omapatrilat.
Desmopressin Desmopressin may decrease the antihypertensive activities of Omapatrilat.
Phentermine Phentermine may decrease the antihypertensive activities of Omapatrilat.
Midodrine Midodrine may decrease the antihypertensive activities of Omapatrilat.
Eletriptan Eletriptan may decrease the antihypertensive activities of Omapatrilat.
Isoetharine Isoetharine may decrease the antihypertensive activities of Omapatrilat.
Methysergide Methysergide may decrease the antihypertensive activities of Omapatrilat.
Cabergoline Cabergoline may decrease the antihypertensive activities of Omapatrilat.
Atomoxetine Atomoxetine may decrease the antihypertensive activities of Omapatrilat.
Etomidate Etomidate may decrease the antihypertensive activities of Omapatrilat.
Zolmitriptan Zolmitriptan may decrease the antihypertensive activities of Omapatrilat.
Dihydroergotamine Dihydroergotamine may decrease the antihypertensive activities of Omapatrilat.
Amitriptyline Amitriptyline may decrease the antihypertensive activities of Omapatrilat.
Protriptyline Protriptyline may decrease the antihypertensive activities of Omapatrilat.
Methylergometrine Methylergometrine may decrease the antihypertensive activities of Omapatrilat.
Norepinephrine Norepinephrine may decrease the antihypertensive activities of Omapatrilat.
Mirtazapine Mirtazapine may decrease the antihypertensive activities of Omapatrilat.
Phenylephrine Phenylephrine may decrease the antihypertensive activities of Omapatrilat.
Phenylpropanolamine Phenylpropanolamine may decrease the antihypertensive activities of Omapatrilat.
Promazine Promazine may decrease the antihypertensive activities of Omapatrilat.
Droperidol Droperidol may decrease the antihypertensive activities of Omapatrilat.
Buspirone Buspirone may decrease the antihypertensive activities of Omapatrilat.
Nortriptyline Nortriptyline may decrease the antihypertensive activities of Omapatrilat.
Amoxapine Amoxapine may decrease the antihypertensive activities of Omapatrilat.
Doxapram Doxapram may decrease the antihypertensive activities of Omapatrilat.
Atropine Atropine may decrease the antihypertensive activities of Omapatrilat.
Lisuride Lisuride may decrease the antihypertensive activities of Omapatrilat.
Metaraminol Metaraminol may decrease the antihypertensive activities of Omapatrilat.

Target Protein

Neprilysin MME
Angiotensin-converting enzyme ACE

Referensi & Sumber

Artikel (PubMed)
  • PMID: 17343842
    Rabkin SW, Klassen SS: Omapatrilat enhances adrenomedullin's reduction of cardiomyocyte cell death. Eur J Pharmacol. 2007 May 21;562(3):174-82. Epub 2007 Feb 8.

Contoh Produk & Brand

Produk: 0 • International brands: 1
International Brands
  • Vanlev

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul